Influenza

Ann Intern Med. 2021 Nov;174(11):ITC161-ITC176. doi: 10.7326/AITC202111160. Epub 2021 Nov 9.

Abstract

Seasonal influenza epidemics of variable severity pose challenges to public health. Annual vaccination is the primary way to prevent influenza, and a wide range of vaccines are available, including inactivated or live attenuated standard-dose, recombinant vaccines, as well as adjuvanted or high-dose vaccines for persons aged 65 years or older. Persons at increased risk for influenza complications include young children, persons with underlying medical conditions, and older adults. Prompt diagnosis of influenza can facilitate early initiation of antiviral treatment that provides the greatest clinical benefit. This article summarizes recommendations for providers on influenza vaccination, diagnostic testing, and antiviral treatment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anaphylaxis / complications
  • Anaphylaxis / prevention & control
  • Antipyretics / therapeutic use
  • Antiviral Agents / therapeutic use
  • Chemoprevention
  • Coinfection / diagnosis
  • Fluid Therapy
  • Hospitalization
  • Humans
  • Infection Control
  • Influenza Vaccines / adverse effects
  • Influenza, Human / complications
  • Influenza, Human / diagnosis*
  • Influenza, Human / therapy*
  • Referral and Consultation
  • Risk Assessment
  • Seasons
  • Vaccine Efficacy

Substances

  • Antipyretics
  • Antiviral Agents
  • Influenza Vaccines